Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $598.92 | 37 | 93.5% |
| Education | $41.51 | 3 | 6.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $139.19 | 7 | $0 (2024) |
| Incyte Corporation | $109.92 | 7 | $0 (2024) |
| Lilly USA, LLC | $79.27 | 6 | $0 (2024) |
| Dermavant Sciences, Inc. | $67.47 | 4 | $0 (2023) |
| Janssen Biotech, Inc. | $64.76 | 4 | $0 (2024) |
| Amgen Inc. | $48.39 | 3 | $0 (2024) |
| UCB, Inc. | $47.79 | 3 | $0 (2024) |
| Galderma Laboratories, L.P. | $28.72 | 2 | $0 (2022) |
| Kyowa Kirin, Inc. | $15.33 | 1 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.15 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $125.39 | 7 | Incyte Corporation ($23.40) |
| 2023 | $184.11 | 11 | Dermavant Sciences, Inc. ($53.47) |
| 2022 | $164.18 | 11 | Incyte Corporation ($41.64) |
| 2021 | $166.75 | 11 | Janssen Biotech, Inc. ($48.89) |
All Payment Transactions
40 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/16/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: Immunology | ||||||
| 10/02/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $23.40 | General |
| Category: Dermatology | ||||||
| 09/18/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.67 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/15/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: Monoclonal Antibody | ||||||
| 02/07/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: Immunology | ||||||
| 01/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: Immunology | ||||||
| 01/10/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: Inflammation | ||||||
| 11/08/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/22/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $15.26 | General |
| Category: Dermatology | ||||||
| 09/07/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: Immunology | ||||||
| 08/11/2023 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $17.04 | General |
| Category: DERMATOLOGY | ||||||
| 07/19/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: Immunology | ||||||
| 06/15/2023 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: DERMATOLOGY | ||||||
| 06/01/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.37 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/04/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $12.83 | General |
| Category: Dermatology | ||||||
| 04/19/2023 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: Immunology | ||||||
| 02/22/2023 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: DERMATOLOGY | ||||||
| 02/15/2023 | Arcutis Biotherapeutics, Inc. | — | Food and Beverage | In-kind items and services | $12.87 | General |
| 11/28/2022 | Dermavant Sciences, Inc. | VTAMA (Drug) | Education | In-kind items and services | $14.00 | General |
| Category: DERMATOLOGY | ||||||
| 11/10/2022 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/26/2022 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $12.57 | General |
| Category: Immunology | ||||||
| 08/11/2022 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/10/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $14.15 | General |
| 06/01/2022 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $11.92 | General |
| Category: Immunology | ||||||
| 05/11/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $16.57 | General |
| Category: Dermatology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 968 | 1,894 | $371,819 | $58,205 |
| 2022 | 12 | 848 | 1,727 | $312,616 | $52,093 |
| 2021 | 13 | 722 | 1,344 | $254,069 | $45,457 |
| 2020 | 14 | 613 | 1,085 | $222,675 | $37,243 |
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 2 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 26 | 29 | $13,327 | $1,649 | 12.4% |
| 69100 | Biopsy of ear | Office | 2022 | 11 | 11 | $4,417 | $504.44 | 11.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 96 | 119 | $38,135 | $8,814 | 23.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 133 | 144 | $31,903 | $8,076 | 25.3% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 88 | 97 | $39,394 | $6,317 | 16.0% |
| 17000 | Destruction of skin growth | Office | 2021 | 126 | 147 | $38,889 | $4,397 | 11.3% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 38 | 48 | $21,759 | $3,300 | 15.2% |
| 17004 | Destruction of 15 or more premalignant skin growths | Office | 2021 | 23 | 26 | $16,657 | $2,712 | 16.3% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 95 | 614 | $14,926 | $2,660 | 17.8% |
| 12032 | Repair of wound (2.6 to 7.5 centimeters) of the scalp, underarms, trunk, arms, and/or legs | Office | 2021 | 11 | 11 | $13,512 | $2,164 | 16.0% |
| 11104 | Punch biopsy of single skin lesion | Office | 2021 | 25 | 25 | $12,763 | $1,979 | 15.5% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2021 | 32 | 48 | $10,365 | $1,779 | 17.2% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 26 | 26 | $8,272 | $1,631 | 19.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 14 | 14 | $6,806 | $1,554 | 22.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 15 | 25 | $689.00 | $75.00 | 10.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 98 | 119 | $36,414 | $7,944 | 21.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 93 | 113 | $23,617 | $5,137 | 21.8% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2020 | 60 | 64 | $25,626 | $3,952 | 15.4% |
| 12032 | Repair of wound (2.6 to 7.5 centimeters) of the scalp, underarms, trunk, arms, and/or legs | Office | 2020 | 17 | 20 | $24,739 | $3,721 | 15.0% |
| 11104 | Punch biopsy of single skin lesion | Office | 2020 | 40 | 44 | $22,148 | $3,695 | 16.7% |
| 17000 | Destruction of skin growth | Office | 2020 | 90 | 106 | $28,042 | $3,049 | 10.9% |
| 17004 | Destruction of 15 or more skin growths | Office | 2020 | 21 | 26 | $16,025 | $2,097 | 13.1% |
| 17110 | Destruction of up to 14 skin growths | Office | 2020 | 31 | 33 | $14,770 | $2,076 | 14.1% |
| 17003 | Destruction of 2-14 skin growths | Office | 2020 | 74 | 459 | $10,502 | $1,809 | 17.2% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2020 | 27 | 38 | $8,205 | $1,406 | 17.1% |
About Jeffrey Weideman, PA-C
Jeffrey Weideman, PA-C is a Medical healthcare provider based in Saint Peter, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2009. The National Provider Identifier (NPI) number assigned to this provider is 1013149079.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jeffrey Weideman, PA-C has received a total of $640.43 in payments from pharmaceutical and medical device companies, with $125.39 received in 2024. These payments were reported across 40 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($598.92).
As a Medicare-enrolled provider, Weideman has provided services to 3,151 Medicare beneficiaries, totaling 6,050 services with total Medicare billing of $192,998. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Practice Information
- Specialty Medical
- Location Saint Peter, MN
- Active Since 08/10/2009
- Last Updated 07/15/2020
- Taxonomy Code 363AM0700X
- Entity Type Individual
- NPI Number 1013149079
Products in Payments
- DUPIXENT (Biological) $139.19
- OPZELURA (Drug) $109.92
- TALTZ (Drug) $79.27
- VTAMA (Drug) $67.47
- TREMFYA (Drug) $64.76
- Otezla (Drug) $48.39
- Cimzia (Drug) $30.92
- Bimzelx (Biological) $16.87
- AKLIEF (Drug) $15.34
- Poteligeo (Drug) $15.33
- ORACEA (Drug) $13.38
- Sotyktu (Drug) $12.57
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.